Investment Rating - The report maintains a "Strong Buy" investment rating for the company [1][7][3] Core Views - The profitability of the downstream breeding sector is gradually improving, leading to a continuous recovery in the company's performance for the first half of 2025. The company achieved a revenue of 487 million yuan, representing a year-on-year increase of 22%, and a net profit attributable to shareholders of 220 million yuan, up 44% year-on-year [7] - The improvement in demand and the rich product matrix have contributed to a sequential improvement in gross margin, which increased by 2.83 percentage points to 68.7% in Q2 2025. The company has also received four new veterinary drug registration certificates, including new vaccines for pigs, which are expected to contribute to profit growth [7] - The anti-involution policy may boost pig prices, which could enhance the demand for animal health products and improve the overall breeding sector's profitability, positively impacting the company's performance [7] Financial Data and Valuation - The company’s total revenue is projected to be 1,064 million yuan in 2023, with a year-on-year growth of 6%. However, a decline of 11% is expected in 2024, followed by a recovery with growth rates of 24%, 14%, and 11% in 2025, 2026, and 2027 respectively [2][13] - The net profit attributable to shareholders is forecasted to be 396 million yuan in 2023, with a slight decline of 3% in 2024, and then a recovery with growth rates of 16%, 14%, and 16% in the following years [2][13] - The company’s price-to-earnings (PE) ratio is expected to decrease from 21.6 in 2023 to 14.5 by 2027, indicating an improving valuation over time [2][14] Stock Performance - The company's stock has shown an absolute performance increase of 55% over the past 12 months, outperforming the benchmark index [5]

Group 1 - The regulatory scrutiny on capital markets remains stringent, with both the auditing firm and the company being penalized for violations [1][2] - The auditing firm, Crowe Horwath, and two signing accountants faced administrative measures due to inadequate audit procedures regarding R&D expenses and long-term equity investments for the company [1] - The company, BioShares, received a warning letter from the Inner Mongolia Securities Regulatory Bureau for three major violations, including inaccurate capitalized R&D expenses and failure to disclose litigation information [2] Group 2 - BioShares reported a significant decline in financial performance for 2024, with revenue of 1.255 billion yuan, down 21.45%, and a net profit of 109 million yuan, down 61.57% [2] - The company anticipates a further decline in net profit for the first half of 2025, projecting between 57 million to 70 million yuan, a decrease of 43.05% to 53.63% year-on-year [3] - Factors contributing to the decline include increased R&D expenses for human antibody drugs, depreciation of intangible assets, intensified competition in the animal health industry, and falling product prices [3]

Investment Rating - Investment recommendation: Outperform the market (maintained) [8] Core Insights - Despite low pig prices, market expectations for future prices have improved due to policy adjustments on sow inventory, pig weight, and breeding scale. The fund's heavy positions in the breeding sector have increased, with a fund heavy position of 0.50% in Q2 2025, up by 0.06 percentage points. The overweight ratio decreased by 0.03 percentage points, up by 0.04 percentage points [5][20] - The feed sector's fund heavy position has significantly increased, supported by the recovery of livestock and aquaculture inventory. The fund heavy position in the feed sector reached 0.52% in Q2 2025, with an overweight ratio of 0.26%, up by 0.11 percentage points [10][20] - The animal health and planting sectors have seen a slight decline in allocation ratios. The fund heavy position in the animal health sector was 0.01%, down by 0.007 percentage points, while the planting sector's heavy position was 0.05%, down by 0.02 percentage points [11][27] Summary by Sections 1. Fund Allocation in Agriculture Sector - The fund allocation in the agriculture sector has slightly increased, with a fund heavy position of 1.09% in Q2 2025, up by 0.17 percentage points. The sector's overweight ratio improved by 0.10 percentage points [16] 2. Investment Recommendations - **Pig Breeding**: In H2 2025, pig supply is expected to remain ample, with prices likely to fluctuate at relatively low levels. Recommended companies include Muyuan Foods, Wens Foodstuff Group, Shennong Group, and Juxing Agriculture [13][37] - **Feed**: Anticipated increases in pig and aquaculture inventory in Q3 may drive demand recovery, benefiting the feed market. Recommended companies include Haida Group and He Feng Group [38] - **Pet Consumption**: The domestic pet economy is experiencing growth, with a focus on local brands. Recommended companies include Zhongchong Co. and Guai Bao Pet [39]

Group 1: Non-ferrous Metals - Tin Industry - The company, Xiyie Co., is a global leader in the tin and indium industry, expected to benefit significantly from the rising price center, leading to profit enhancement. The company has excellent resource endowments with substantial growth potential in tin, tungsten, and indium production [2][4]. - The domestic market share of the company in tin metal is projected to reach 47.98% in 2024, with a global market share of 25.03%, positioning it as the top tin producer worldwide. The company plans to invest 101 million yuan in exploration, adding 52,400 tons of non-ferrous metal resources in 2024 [4]. - The company is actively pursuing both internal resource development and external partnerships to enhance its industry chain advantages, with a production scale of 1.5 million tons/year for tin and 560,000 tons/year for tungsten planned [4][5]. Group 2: Agriculture - Animal Health Industry - Ruip Bio is a leading player in the domestic animal health industry, with robust growth in both livestock and pet health segments. The company is expected to see steady progress in livestock health and rapid growth in pet health products, with a projected market size of 20.95 billion yuan for pet medicine by 2024 [6][7]. - The company has achieved a compound annual growth rate of over 16% in revenue from 2015 to 2024, with total revenue expected to reach 3.07 billion yuan in 2024. The company has established a strong presence in over 70 cities through strategic acquisitions and partnerships [7]. - The company is focusing on enhancing its product matrix in pet health, with a significant emphasis on vaccine development, including a breakthrough in the cat trivalent vaccine, which is expected to double revenue in 2025 [6][7]. Group 3: Communication - New Yi Sheng - New Yi Sheng has raised its earnings forecast and target price, maintaining a buy rating. The company is expected to achieve a net profit of 3.7 to 4.2 billion yuan in the first half of 2025, representing a year-on-year growth of 327.68% to 385.47% [9][10]. - The company is expanding its production capacity, with the first phase of its factory in Thailand completed in the first half of 2023 and the second phase expected to be operational in early 2025. The demand for 1.6T products is anticipated to begin ramping up in the second half of 2025 [10].

Transaction Overview - The company plans to transfer 48.4213% equity of its subsidiary, Hunan Zhong'an Biological Pharmaceutical Co., Ltd. (Zhong'an Bio), to Jiangxi Twin Biological Technology Co., Ltd. for a transaction price of approximately 11.48 million yuan, based on a total equity value of 23.7 million yuan [1][2][16] - After the transaction, the company will hold 20% of Zhong'an Bio's equity, which will no longer be included in the company's consolidated financial statements [2][24] Fundraising Project Progress - The company raised approximately 1.34 billion yuan through a private placement of 63,984,674 shares at a price of 20.88 yuan per share, with a net amount of approximately 1.33 billion yuan after deducting issuance costs [2][3] - The funds raised are allocated to various projects, including the Zhong'an Bio expansion project, which has reached a usable state and has been completed [5][6] Financial Performance of Zhong'an Bio - As of December 31, 2024, Zhong'an Bio reported a net asset value of approximately 20.55 million yuan, with total assets of approximately 31.77 million yuan and total liabilities of approximately 11.22 million yuan [14][16] - The company experienced a net loss of approximately 45.96 thousand yuan in 2024, compared to a net profit of approximately 10.08 million yuan in 2023 [15][16] Strategic Cooperation - The transaction establishes a strategic partnership between the company and Jiangxi Twin Biological, focusing on vaccine and drug research, product procurement, and disease prevention in the livestock industry [20][24] - Both parties aim to enhance their capabilities in disease prevention and control, leveraging shared resources and expertise [21][22] Board and Supervisory Opinions - The company's board and supervisory committee have approved the equity transfer and fundraising project transfer, stating that it aligns with the company's long-term development strategy and does not harm the interests of shareholders [25][26]

Group 1: Financial Performance - The company's revenue for Q1 2025 reached 625.15 million CNY, representing a year-on-year growth of 20.35% [2] - The net profit attributable to shareholders for the same period was 51.12 million CNY, with a year-on-year increase of 13.23% [2] - The veterinary chemical drug revenue increased by 21.47% year-on-year, driven primarily by the sales of the product "Jinmei" [1] Group 2: Product Development and Market Strategy - The company plans to expand its product line with the new factory set to produce Jinmei, Tumei, and Qiangli products, enhancing its product diversity [1] - The R&D expenses grew by 27.03% in 2024, focusing on innovation and new product development [2] - The company has 16 vaccine products currently on the market and over 20 in the research and application phase [2] Group 3: Market Expansion and Competitive Advantage - The company exports 60-70% of its chemical products, with the U.S. being the primary market [5] - The introduction of the hydrochloride doxycycline project is expected to generate over 300 million CNY in revenue [3] - The company aims to enhance its market share in the veterinary vaccine sector by providing comprehensive technical solutions alongside its products [3] Group 4: Future Outlook and Industry Trends - The domestic veterinary drug market has a compound annual growth rate (CAGR) of 8.43% from 2019 to 2023, indicating significant growth potential [5] - The company anticipates that the market for veterinary biological products will expand, particularly with the ongoing development of the African swine fever vaccine [5] - The company is committed to strengthening its global presence and optimizing resource allocation to seize opportunities in the veterinary industry [6]

Investment Rating - The investment rating for the company is "Add" and maintained [1] Core Views - The company reported a significant decline in revenue and net profit for the year 2024, with total revenue of 1.043 billion yuan, down 16.77% year-on-year, and a net profit of 93 million yuan, down 46.82% year-on-year. However, the first quarter of 2025 showed a recovery with revenue of 279 million yuan, up 18.32% year-on-year, and a net profit of 53 million yuan, up 93.75% year-on-year, driven by growth in poultry vaccines and pharmaceuticals [4][5] - The company is facing pressure in the pig vaccine segment due to increased competition, while the poultry vaccine and pharmaceutical segments are showing growth. The pet vaccine segment is also emerging as a new growth area, with sales exceeding 46 million yuan in 2024 [5] - The company is implementing marketing strategy adjustments and organizational changes to strengthen cost control and core competitiveness, anticipating a recovery in performance as the pig vaccine market stabilizes and new growth opportunities in pet vaccines arise [6] Financial Summary - The company’s financial performance is projected to improve from 2025 to 2027, with expected earnings per share (EPS) of 0.49 yuan, 0.61 yuan, and 0.68 yuan respectively. The revenue is expected to grow from 1.131 billion yuan in 2025 to 1.259 billion yuan in 2027, with net profit projected to increase from 169 million yuan to 237 million yuan over the same period [7][9]

Investment Rating - The investment rating for the company is "Add" and it is maintained [1] Core Views - The company reported a significant decline in revenue and net profit for the year 2024, with total revenue of 1.043 billion yuan, down 16.77% year-on-year, and a net profit of 93 million yuan, down 46.82% year-on-year. However, in Q1 2025, the company showed signs of recovery with a revenue of 279 million yuan, up 18.32% year-on-year, and a net profit of 53 million yuan, up 93.75% year-on-year, driven by growth in poultry vaccines and pharmaceuticals [4][5] - The performance of different vaccine products varies significantly, with poultry vaccines showing continuous growth, while pig vaccines are under pressure due to increased competition in the swine breeding industry. The company’s revenue from poultry vaccines and antibodies increased by 3.31% and 33.80% respectively in 2024 and Q1 2025, while revenue from pig vaccines decreased by 22.58% and 11.64% respectively [5] - The company is expected to recover as it adjusts its marketing strategy and implements organizational changes, with projected EPS for 2025-2027 being 0.49 yuan, 0.61 yuan, and 0.68 yuan respectively, maintaining an "Add" rating [6] Company Overview - The latest closing price of the company's stock is 13.70 yuan, with a total market capitalization of 4.7 billion yuan. The company has a total share capital of 346 million shares, with a debt-to-asset ratio of 15.2% and a P/E ratio of 50.74 [3][4]